Bioquímica y Biología Molecular
Departamento
National and Kapodistrian University of Athens
Atenas, GreciaPublicaciones en colaboración con investigadores/as de National and Kapodistrian University of Athens (20)
2024
-
Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence–Assisted ARIA Care Pathways (ARIA 2024)
Journal of Allergy and Clinical Immunology: In Practice, Vol. 12, Núm. 10, pp. 2648-2668.e2
2023
-
Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 5, pp. 1169-1203
2021
-
COVID-19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 3, pp. 648-676
-
EAACI Biologicals Guidelines—Recommendations for severe asthma
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 14-44
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
Management of anaphylaxis due to COVID-19 vaccines in the elderly
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 10, pp. 2952-2964
2020
-
Anwendung von biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie
Allergologie, Vol. 43, Núm. 7, pp. 255-271
-
Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 11, pp. 2764-2774
-
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1043-1057
-
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1023-1042
-
Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1058-1068
2019
-
EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 74, Núm. 5, pp. 855-873
-
IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy
Journal of Allergy and Clinical Immunology: In Practice, Vol. 7, Núm. 5, pp. 1418-1429
-
Severe asthma: Entering an era of new concepts and emerging therapies: Highlights of the 4th international severe asthma forum, Madrid, 2018
Allergy: European Journal of Allergy and Clinical Immunology
2017
-
European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS)
Redox Biology, Vol. 13, pp. 94-162
2016
2015
-
CEND1 and NEUROGENIN2 Reprogram Mouse Astrocytes and Embryonic Fibroblasts to Induced Neural Precursors and Differentiated Neurons
Stem Cell Reports, Vol. 5, Núm. 3, pp. 405-418
2012
-
Guidelines for the use and interpretation of assays for monitoring autophagy
Autophagy, Vol. 8, Núm. 4, pp. 445-544